Edwards Lifesciences Corporation $EW Shares Sold by Fideuram Intesa Sanpaolo Private Banking S.P.A.

Fideuram Intesa Sanpaolo Private Banking S.P.A. reduced its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 41.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,247 shares of the medical research company’s stock after selling 7,826 shares during the quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Edwards Lifesciences were worth $901,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Edwards Lifesciences by 27.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after buying an additional 23,514 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Edwards Lifesciences by 39.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock worth $194,907,000 after buying an additional 648,870 shares in the last quarter. Central Pacific Bank Trust Division acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $775,000. Sivik Global Healthcare LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $2,984,000. Finally, Stance Capital LLC lifted its position in shares of Edwards Lifesciences by 373.1% in the third quarter. Stance Capital LLC now owns 45,994 shares of the medical research company’s stock valued at $3,577,000 after acquiring an additional 36,272 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on EW shares. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research note on Tuesday, June 16th. TD Cowen reissued a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. BTIG Research raised their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Finally, Evercore reiterated an “outperform” rating and set a $93.00 price target on shares of Edwards Lifesciences in a report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $96.39.

Edwards Lifesciences Price Performance

EW stock opened at $94.31 on Friday. The stock has a market capitalization of $54.31 billion, a price-to-earnings ratio of 50.17, a price-to-earnings-growth ratio of 2.37 and a beta of 0.86. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $94.47. The stock’s fifty day simple moving average is $85.61 and its 200-day simple moving average is $83.57.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same period in the prior year, the firm posted $0.64 earnings per share. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares in the company, valued at $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 58,977 shares of company stock valued at $4,921,803. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.